J. Stevens

发表

University of Groningen Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight Koomen,

H. Parving, H. Heerspink, D. Zeeuw, 2018 .

Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight

H. Parving, D. de Zeeuw, H. Heerspink, 2018, Diabetes, obesity & metabolism.

Optimizing the glutamatergic challenge model for psychosis, using S(+)-ketamine to induce psychomimetic symptoms in healthy volunteers

A. Dahan, J. V. van Gerven, J. Freijer, 2015, Journal of psychopharmacology.

The power of modelling pulsatile profiles

J. Stevens, M. V. van Esdonk, 2021, Journal of pharmacokinetics and pharmacodynamics.

A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds

P. H. van der Graaf, J. Stevens, J. Burggraaf, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects

M. D. de Kam, J. Stevens, G. Groeneveld, 2018, CPT: pharmacometrics & systems pharmacology.

The use of a battery of pain models to detect analgesic properties of compounds: a two‐part four‐way crossover study

A. Dahan, J. V. van Gerven, R. Butt, 2017, British journal of clinical pharmacology.

Simplified Iohexol-Based Method for Measurement of Glomerular Filtration Rate in Goats and Pigs

M. Verhaar, J. Stevens, J. Joles, 2021, Biology.

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials

Jeroen V Koomen, J. Stevens, H. Heerspink, 2020, British journal of clinical pharmacology.

An anti‐nicotinic cognitive challenge model using mecamylamine in comparison with the anti‐muscarinic cognitive challenge using scopolamine

J. V. van Gerven, E. Swart, J. Stevens, 2017, British journal of clinical pharmacology.

UHPLC-MS/MS method for iohexol determination in human EDTA and lithium-heparin plasma, human urine and in goat- and pig EDTA plasma.

R. Gansevoort, J. Stevens, D. Touw, 2020, Bioanalysis.

Safety and dose‐dependency of eptacog beta (activated) in a dose escalation study of non‐bleeding congenital haemophilia A or B patients, with or without inhibitors

M. Wang, L. Boggio, M. Moerland, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M 1 -acetylcholine receptor agonist: A randomized cross-over trial

M. Congreve, F. Marshall, P. Nathan, 2021 .

Levofloxacin‐Induced QTc Prolongation Depends on the Time of Drug Administration

M. Danhof, V. Gotta, J. Stevens, 2016, CPT: pharmacometrics & systems pharmacology.

Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

J. McMurray, H. Parving, G. Bakris, 2020, Diabetes, obesity & metabolism.

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

D. Grobbee, A. Lincoff, H. Heerspink, 2019, Diabetes, obesity & metabolism.

Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease

G. Laverman, M. Vervloet, H. Heerspink, 2021, Clinical Pharmacokinetics.

GMP Compliant Synthesis of [18F]Canagliflozin, a Novel PET Tracer for the Sodium–Glucose Cotransporter 2

A. Heeres, H. van Goor, H. Boersma, 2021, Journal of medicinal chemistry.

Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

J. McMurray, H. Parving, G. Bakris, 2020, Clinical pharmacology and therapeutics.

Mechanism-based PK–PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans

B. Ploeger, M. Danhof, J. Stevens, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Caffeine pharmacokinetics and effects on central and autonomous nervous system parameters in adolescents

R. Mathôt, J. Stevens, J. Burggraaf, 2015 .

Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge tests.

J. V. van Gerven, J. Stevens, J. Heuberger, 2015, British journal of clinical pharmacology.

The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol

P. Spinhoven, J. Stevens, J. V. Gerven, 2014, Psychiatry Research.

Quantifying Beta‐Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling

T. Hankemeier, J. Stevens, A. Verma, 2016, Clinical and translational science.

University of Groningen Quantifying Beta-Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling Kanhai,

T. Hankemeier, J. Stevens, A. Verma, 2016 .

The pharmacodynamic effects of a dopamine-somatostatin chimera agonist on the cardiovascular system.

J. Stevens, J. Burggraaf, F. Stuurman, 2019, Journal of cardiovascular pharmacology.

The relationship between caries-specific quality of life and generic wellbeing in a Dutch pediatric population

J. Stevens, J. Burggraaf, P. Graaf, 2019 .

A New Minimal-Stress Freely-Moving Rat Model for Preclinical Studies on Intranasal Administration of CNS Drugs

M. Danhof, P. H. van der Graaf, J. Stevens, 2009, Pharmaceutical Research.

University of Groningen A new minimal-stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs Stevens, Jasper; Suidgeest,

M. Danhof, J. Stevens, E. Suidgeest, 2009 .

Nonlinear mixed effects evaluation of Hamilton Depression Rating Score following combination treatment of presynaptic- and postsynaptic glutamate receptor inhibitors in bipolar depression patients

A. Anand, R. Bies, A. Shekhar, 2012 .

Fosfomycin: Pharmacological, Clinical and Future Perspectives

J. Stevens, D. Touw, C. van Nieuwkoop, 2017, Antibiotics.

Current Use and Complementary Value of Combining in Vivo Imaging Modalities to Understand the Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors at a Tissue Level

J. Stevens, Sjoukje van der Hoek, 2022, Frontiers in Pharmacology.

Population Pharmacokinetics of Prednisolone in Relation to Clinical Outcome in Children With Nephrotic Syndrome

J. Nauta, R. V. van Schaik, M. Ackermans, 2016, Therapeutic drug monitoring.

How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review

P. H. van der Graaf, F. Roelfsema, J. Stevens, 2018, Pituitary.

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin

D. de Zeeuw, H. Heerspink, J. Stevens, 2019, Diabetes, obesity & metabolism.

Biodistribution and translational pharmacokinetic modeling of a human recombinant alkaline phosphatase.

P. Pickkers, P. Laverman, R. Masereeuw, 2015, International journal of pharmaceutics.

Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples.

M. Danhof, P. H. van der Graaf, H. Niederländer, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Systemic and Direct Nose-to-Brain Transport Pharmacokinetic Model for Remoxipride after Intravenous and Intranasal Administration

B. Ploeger, M. Danhof, P. H. van der Graaf, 2011, Drug Metabolism and Disposition.

Mechanism-based PK–PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans

B. Ploeger, M. Danhof, J. Stevens, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Model informed quantification of the feed‐forward stimulation of growth hormone by growth hormone‐releasing hormone

P. H. van der Graaf, J. Stevens, J. Burggraaf, 2020, British journal of clinical pharmacology.

University of Groningen Model informed quantification of the feed-forward stimulation of growth hormone by growth hormone releasing hormone

J. Stevens, J. Burggraaf, J. V. D. Graaf, 2020 .

Retinol Binding Proteinuria and Phosphaturia: Markers of Paracetamol-Induced Nephrotoxicity

J. Stevens, C. Florkowski, D. Husband, 1994, Annals of clinical biochemistry.

Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modeling

P. H. van der Graaf, J. Stevens, J. Burggraaf, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

Effect of Food on the Pharmacokinetics of 2 Formulations of DRL‐17822, a Novel Selective Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Males

B. Padhi, A. Gautam, J. Stevens, 2019, Clinical pharmacology in drug development.

Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers

G. Laverman, H. Heerspink, J. Stevens, 2020, Diabetes, obesity & metabolism.

University of Groningen Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers Kroonen,

H. Heerspink, J. Stevens, S. Petrykiv, 2020 .

Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1‐acetylcholine receptor agonist: A randomized cross‐over trial

M. Congreve, F. Marshall, P. Nathan, 2021, British journal of clinical pharmacology.

Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens

J. Stevens, D. Touw, C. van Nieuwkoop, 2018, Pharmacology research & perspectives.

Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers

P. Pickkers, R. Masereeuw, A. van Elsas, 2016, Clinical Pharmacokinetics.

Identifying 24 h variation in the pharmacokinetics of levofloxacin: a population pharmacokinetic approach.

T. de Boer, J. Meijer, J. Stevens, 2016, British journal of clinical pharmacology.

First in human study with a prodrug of galantamine: Improved benefit-risk ratio?

A. Maelicke, J. Stevens, G. Groeneveld, 2016, Alzheimer's & dementia.

Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection

J. Stevens, C. van Nieuwkoop, J. Burggraaf, 2020, The Journal of antimicrobial chemotherapy.

Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies

J. Stevens, J. Burggraaf, J. Reijers, 2016, European Journal of Clinical Pharmacology.

Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration

J. Stevens, D. Touw, J. Burggraaf, 2017, European journal of hospital pharmacy. Science and practice.

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe

P. Mol, H. Heerspink, J. Stevens, 2021, Frontiers in Pharmacology.

Pharmacological interactions between brivaracetam and ethanol in healthy males

J. V. van Gerven, M. D. de Kam, J. Stevens, 2017, Journal of psychopharmacology.

Pharmacokinetics and pharmacodynamics of oral mecamylamine – development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation

J. V. van Gerven, E. Hart, J. Stevens, 2017, Journal of psychopharmacology.

Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.

J. Stevens, G. Groeneveld, S. Goulooze, 2016, British journal of clinical pharmacology.

The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL‐17822 in healthy male volunteers

A. Gautam, J. Stevens, J. Burggraaf, 2020, British journal of clinical pharmacology.

Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects

J. V. van Gerven, P. Nathan, D. Mayleben, 2016, Journal of psychopharmacology.

A Phase Ib, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Coagulation Factor VIIa in Congenital Hemophilia A or B

J. Stevens, M. Simpson, J. Burggraaf, 2016 .

Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [ 11C]Telmisartan

A. Heeres, A. Willemsen, R. Slart, 2022, Clinical pharmacology and therapeutics.

University of Groningen Population pharmacokinetic/pharmacodynamic analysis of nociceptive pain models following an oral pregabalin dose administration to healthy subjects

J. Stevens, G. Groeneveld, P. Okkerse, 2018 .